Inappropriate activation of Toll-like receptor 4 (TLR4) on resident fibroblasts, through the binding of damage-associated molecular patterns, is a potential driver of fibrosis in systemic sclerosis. New evidence suggests that targeting fibroblast-specific TLR4 or an accessory molecule MD2 could have therapeutic value.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Elhai, M. et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 51, 1017–1026 (2012).
O’Reilly, S. Toll like receptors in systemic sclerosis: an emerging target. Immunol. Lett. 195, 2–8 (2018).
Fullard, N. & O’Reilly, S. Role of innate immune system in systemic sclerosis. Sem. Immunopathol. 37, 511–517 (2015).
Bhattacharyya, S. et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight 3, e98850 (2018).
Bhattacharyya, S. et al. Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am. J. Pathol. 182, 192–205 (2013).
Bhattacharyya, S. et al. Tenascin-C drives persistence of organ fibrosis. Nat. Commun. 7, 11703 (2016).
Milano, A. et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3, e2696 (2008).
Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex. Nature 458, 1191 (2009).
Dowson, C. et al. Innate immunity in systemic sclerosis. Curr. Rheumatol. Rep. 19, 2 (2017).
Opal, S. M. et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA 309, 1154–1162 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
O’Reilly, S., van Laar, J.M. Targeting the TLR4–MD2 axis in systemic sclerosis. Nat Rev Rheumatol 14, 564–566 (2018). https://doi.org/10.1038/s41584-018-0077-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0077-6
This article is cited by
-
Novel role of long non-coding RNAs in autoimmune cutaneous disease
Journal of Cell Communication and Signaling (2022)
-
Macrophages in Systemic Sclerosis: Novel Insights and Therapeutic Implications
Current Rheumatology Reports (2019)